<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01730209</url>
  </required_header>
  <id_info>
    <org_study_id>NL38619.078.11</org_study_id>
    <nct_id>NCT01730209</nct_id>
  </id_info>
  <brief_title>Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex</brief_title>
  <acronym>RAPIT</acronym>
  <official_title>Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Utrecht University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberous sclerosis complex (TSC) is a genetic disease that leads to mental retardation in
      over 50% of patients, and to learning problems, behavioral problems, autism and epilepsy in
      up to 90% of patients. The underlying deficit of TSC, loss of inhibition of the mammalian
      target of rapamycin (mTOR) protein due to dysfunction of the tuberin/hamartin protein
      complex, can be rescued by everolimus. Everolimus has been registered as treatment for renal
      cell carcinoma and giant cell astrocytoma (SEGA). Evidence in human and animal studies
      suggests that mTOR inhibitors improve learning and development in patients with TSC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized double-blind placebo controlled intervention study in children with TSC between
      age 4 and 15 years with an intelligence quotient (IQ) estimated &lt;80 and/or special schooling
      and/or autism spectrum disorder and/or learning disability requiring remedial teaching.

      Patients are randomised to receive everolimus or placebo during a period of 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive ability measured by IQ</measure>
    <time_frame>12 months</time_frame>
    <description>Assessed by Wechsler scales: Wechsler Preschool and Primary Scale of Intelligence (WPPSI-III NL) and Wechsler Intelligence Scale for Children (WISC-III-NL)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Autistic features</measure>
    <time_frame>12 Months</time_frame>
    <description>Assessed by Autism Diagnostic Observation Schedule (ADOS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social and communicational skills</measure>
    <time_frame>12 Months</time_frame>
    <description>Assessed by social responsiveness scale (SRS) and Dutch Children's Communication Checklist (CCC-2-NL) questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Working memory and attention, information processing</measure>
    <time_frame>6 and 12 Months</time_frame>
    <description>Assessed by Cambridge Neuropsychological Test Automated Battery (CANTAB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual-motor integration</measure>
    <time_frame>12 Months</time_frame>
    <description>Assessed by BEERY Visual-Motor Integration (BEERY VMI), grooved pegboard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child behavior</measure>
    <time_frame>12 Months</time_frame>
    <description>Assessed by Child Behavior Checklist (CBCL) and Teacher's Report Form (TRF) questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Executive functioning</measure>
    <time_frame>12 Months</time_frame>
    <description>Assessed by Behavior Rating Inventory of Executive Functioning (BRIEF) questionnaire Dutch version</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleeping problems</measure>
    <time_frame>12 Months</time_frame>
    <description>Assessed by Sleep Disturbance Scale for Children (SDSC) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child health</measure>
    <time_frame>12 Months</time_frame>
    <description>Assessed by Child Health Questionnaire Parent Form (CHQ-PF50) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory related difficulties</measure>
    <time_frame>12 Months</time_frame>
    <description>Assessed by Short Sensory Profile (SSP) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epilepsy</measure>
    <time_frame>12 Months</time_frame>
    <description>Comparison of epilepsy frequency during month previous to study start and last month of trial participation.
EEG abnormalities</description>
  </secondary_outcome>
  <other_outcome>
    <measure>School level</measure>
    <time_frame>12 Months</time_frame>
    <description>Assessed by the school CITO (centraal instituut voor toetsontwikkeling) scores or reading and arithmetic scores</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>12 Months</time_frame>
    <description>Assessed by measuring trough levels of everolimus</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety</measure>
    <time_frame>12 Months</time_frame>
    <description>Levels of and abnormalities in blood control values</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Tuberous Sclerosis Complex</condition>
  <condition>TSC Related Cognitive Disability</condition>
  <condition>TSC Related Autism</condition>
  <condition>TSC Related Learning Problems</condition>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus once daily for 1 year, titration to trough levels of 5-10 ng/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment for 1 year. Tablets will be identical to everolimus tablets.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus once daily titrated to trough levels of 5-10 ng/ml.</description>
    <arm_group_label>Everolimus</arm_group_label>
    <other_name>RAD001</other_name>
    <other_name>Votubia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children with a definite diagnosis of TSC between 4 and 15 years.

          -  With an IQ estimated &lt;80 and/or special schooling and/or autism spectrum disorder
             and/or learning disability requiring remedial teaching.

          -  Written informed consent by parents/care-takers, and the patient if he or she is 12
             years or older and cognitively able to consent.

          -  In girls after menarche, appropriate contraception must be used or abstinence
             practiced.

        Exclusion Criteria:

          -  Hepatic dysfunction

          -  Surgery &lt;6wk

          -  Current infection at time of inclusion

          -  Developmental age estimated below 3.5 years

          -  Intractable epilepsy with more than 1 seizure/week

          -  Inability to comply with the treatment protocol

          -  Additional diseases or disorders that may influence the endpoints, including:

               -  SEGA requiring treatment

               -  Uncontrolled diabetes mellitus

               -  Known impaired lung function

          -  Allergy for any of the components of the study medication

          -  Prior treatment with mTOR inhibitors

          -  HIV seropositivity

          -  Bleeding diathesis or oral anti-vitamin K medication

          -  Serum creatinine &gt; 1.5 x ULN

          -  Uncontrolled hyperlipidemia (fasting serum cholesterol &gt; 7.75 mmol/L, fasting serum
             triglycerides &gt; 2.5 x ULN)

          -  Use of investigational drug within 30 days prior to inclusion

          -  History of myocardial infarction, angina or stroke related to atherosclerosis, organ
             transplantation, malignancy in the past 2 years

          -  Pregnancy or breastfeeding

          -  Children at risk for Hepatitis B (HB), unless hepatitis B serology is normal. Risk
             groups are children who have lived in Asia, Africa, Central and South America, Eastern
             Europe, Spain, Portugal, and Greece, children with known or suspected past or current
             hepatitis B infection, current or prior IV illicit drug use, current or prior
             dialysis, household contact with hepatitis B infected patient(s), current or prior
             high-risk sexual activity, body piercing or tattoos, mother known to have hepatitis B
             history. If vaccinated, presence of HBs Ab is normal.

          -  Known or suspected hepatitis C infection, unless hepatitis C serology is normal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>M.C.Y. de Wit, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>M.C.Y. de Wit, MD. PhD.</last_name>
    <phone>+31 10 703 6956</phone>
    <email>tubereuzesclerose@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M.C.Y. de Wit, MD. PhD.</last_name>
      <phone>+31 10 703 6956</phone>
      <email>tubereuzesclerose@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>M.C.Y. de Wit, MD. PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>I.E. Overwater, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.erasmusmc.nl/encore/?lang=en</url>
    <description>ENCORE TSC expertise center</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2012</study_first_submitted>
  <study_first_submitted_qc>November 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2012</study_first_posted>
  <last_update_submitted>May 4, 2015</last_update_submitted>
  <last_update_submitted_qc>May 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>M.C.Y. de Wit, MD PhD</investigator_full_name>
    <investigator_title>Pediatric Neurologist</investigator_title>
  </responsible_party>
  <keyword>Tuberous Sclerosis Complex</keyword>
  <keyword>TSC</keyword>
  <keyword>Autism</keyword>
  <keyword>Learning problems</keyword>
  <keyword>Everolimus</keyword>
  <keyword>RAD001</keyword>
  <keyword>Treatment</keyword>
  <keyword>Cognition</keyword>
  <keyword>Intellectual disability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Tuberous Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

